{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Efficacy will be measured according to 2017 RECIL criteria. Responses will be assessed by the investigator and will be based on PET/CT scan to be obtained after 6 cycles of induction chemotherapy. Complete response (CR), complete disappearance of all target lesions and Deauville score 1-3. Partial response (PR), ≥30% decrease in the sum of longest diameters of target lesions but not a CR and Deauville score 4-5. Stable disease (SD), \\<30% decrease or ≤ 20% increase in the sum of longest diameters of target lesions. Progressive disease (PD), \\>20% increase in the sum of longest diameters of target lesions, For small lymph nodes measuring \\< 15 mm post-therapy, a minimum of 5 mm increase in longest diameter to \\> 15 mm, or new lesions.","groups":[{"description":"Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.","id":"OG000","title":"Nivo and EPOCH"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients on trial.","reportingStatus":"POSTED","timeFrame":"up to 100 days post transplant","title":"Efficacy: Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}